Avantor Taps Danaher Veteran Brellier to Lead Bioscience Unit and Transformation
Event summary
- Ludovic Brellier joins Avantor as EVP of Bioscience & Medtech Products and Chief Transformation Officer on May 1, 2026.
- Brellier previously led Cytiva's Hardware Solutions business at Danaher, overseeing biopharma innovation and commercialization.
- He will drive growth in the BMP segment and lead Avantor's 'Revival' transformation initiatives.
- Current BMP EVP Benoit Gourdier will stay until year-end 2026 to ensure transition.
The big picture
Avantor's hire of Ludovic Brellier underscores its push to revitalize the bioscience segment amid competitive pressures in life sciences tools. The move follows a trend of cross-industry talent acquisition targeting operational efficiency and scalable growth platforms. With Brellier's Danaher background, Avantor aims to leverage his experience in bioprocessing innovation and commercialization to drive performance improvements.
What we're watching
- Execution Risk
- How Brellier's track record at Cytiva will translate to Avantor's BMP segment and broader transformation efforts.
- Growth Strategy
- Whether Avantor can sustain organic and inorganic growth in bioprocessing under new leadership.
- Integration Challenges
- The pace at which Brellier can integrate his operational expertise into Avantor's existing structure.